The Critical Heuristics of Iranian Banking Credit System: Analysis of the Antithetical Opinions of the Beneficiaries

2020 ◽  
Vol 33 (3) ◽  
pp. 363-392
Author(s):  
Mahmoud Dehghan Nayeri ◽  
Moein Khazaei ◽  
Fatemeh Alinasab-Imani
2002 ◽  
Vol 34 (1) ◽  
pp. 71-114 ◽  
Author(s):  
JENNIFER HERMANN

The article analyses the Brazilian experience in financing economic activity from the 1964–67 reform until the 1990s. Two issues are addressed: first, what conditions explain the development of a model based on public and external credit in Brazil, quite different from the capital market based system conceived in the 1964–67 reform? Second, what are the perspectives for the development of an alternative model in the country, led by the national private sector? Based on international experience, two alternatives are considered: a) the expansion of the capital market, in order to make possible large scale direct financing; b) the formation of a private banking credit system, complementing or replacing both public and external credit. Despite undoubted improvements, tendencies observed up to 1997 suggest the persistence of the ‘short-termist’ profile that typically characterised the Brazilian financial system. Thus, the development of both capital market and banking credit models depends on financial policies devoted to this goal. General guidelines for such policies are suggested in the last section of the paper.


2005 ◽  
Author(s):  
K. L. Calvin ◽  
Gail R. Casper ◽  
Ben-Tzion Karsh ◽  
Patricia F. Brennan ◽  
Laura J. Burke ◽  
...  

2020 ◽  
Vol 17 (1) ◽  
pp. 58-67
Author(s):  
N. A. Kabanova ◽  
I. K. Alekseeva

The article is devoted to the assessment of potential investment risks of the pharmaceutical company “R-Pharm” JSC with the aim of identifying the highest priority risks and developing methods for minimizing them. The relevance of the study is determined by the fact that the pharmaceutical business is characterized by a high degree of social orientation and annually invests $ 140 billion in the development of production and research, which determines the need for a risk-based approach to ensure the return on investment. The subject of this article is the investment risks of pharmaceutical companies, and the subject of research is the domestic pharmaceutical company “R-Pharm”. In order to assess the potential investment risks of “R-Pharm” JSC, the authors used elements of simulation modeling and system analysis. The proposed methods to minimize key investment risks are aimed at improving the efficiency of investment activities and is recommended as an element of the strategic planning of the company.


Sign in / Sign up

Export Citation Format

Share Document